BLSM to present updated SOLARA Phase 1/2 trial data
BlossomHill Therapeutics will present updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.